2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。本次会议聚焦肿瘤治疗前沿，将呈现化疗、内分泌治疗、免疫治疗、靶向治疗及精准医学的最新进展。日前，官网已经公布各项研究摘要，本文特将消化领域重磅研究进展进行汇总，以飨读者。
编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。本次会议聚焦肿瘤治疗前沿，将呈现化疗、内分泌治疗、免疫治疗、靶向治疗及精准医学的最新进展。日前，官网已经公布各项研究摘要，本文特将消化领域重磅研究进展进行汇总，以飨读者。（摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布）
口头报告
胃食管癌及肝胆胰癌专场
Gastrointestinal Cancer—Gastroesophageal，Pancreatic，and Hepatobiliary
美国东部时间：5月31日15:00–18:00
北京时间：6月1日04:00–07:00
地点：Hall D1
胃/胃食管结合部癌
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer(EC/GEJC)following neoadjuvant chemoradiotherapy(CRT):First results of overall survival(OS)from CheckMate 577.
CheckMate 577研究：纳武利尤单抗辅助治疗用于新辅助放化疗（CRT）后切除的食管癌或胃食管结合部癌（EC/GEJC）：总生存期（OS）的首次结果
讲者:Ronan Joseph Kelly，MD，MBA，FASCO|Charles A.Sammons Cancer Center at Baylor University Medical Center
摘要号:4000
报告时间：15:00-15:12
Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced，metastatic gastroesophageal adenocarcinoma:The phase 3，randomized LEAP-015 study.
LEAP-015研究：仑伐替尼联合帕博利珠单抗及化疗对比化疗治疗晚期转移性胃食管腺癌，III期随机研究LEAP-015
讲者:Sun Young Rha，MD，PhD|Yonsei Cancer Center，Yonsei University College of Medicine
摘要号:4001
报告时间：15:12-15:24
Trastuzumab deruxtecan(T-DXd)vs ramucirumab(RAM)+paclitaxel(PTX)in second-line treatment of patients(pts)with human epidermal growth factor receptor 2-positive(HER2+)unresectable/metastatic gastric cancer(GC)or gastroesophageal junction adenocarcinoma(GEJA):Primary analysis of the randomized，phase 3 DESTINY-Gastric04 study.
DESTINY-Gastric04研究：德曲妥珠单抗（T-DXd）对比雷莫西尤单抗（RAM）+紫杉醇（PTX）二线治疗HER2阳性不可切除/转移性胃癌（GC）或胃食管结合部腺癌（GEJA），III期随机研究DESTINY-Gastric04初步分析
讲者:Kohei Shitara，MD|National Cancer Center Hospital East
摘要号:LBA4002
报告时间：15:24-15:36
Claudin18.2-specific CAR T cells(Satri-cel)versus treatment of physician’s choice(TPC)for previously treated advanced gastric or gastroesophageal junction cancer(G/GEJC):Primary results from a randomized，open-label，phase II trial(CT041-ST-01).
CT041-ST-01研究：特异性靶向Claudin18.2的CAR-T细胞（Satri-cel）疗效对比医生选择方案（TPC）治疗经治晚期胃癌或胃食管结合部癌（G/GEJC）：随机、开放标签II期研究（CT041-ST-01）初步结果
讲者:齐长松教授|北京大学肿瘤医院
摘要号:4003
报告时间：15:36-15:48
胰腺癌
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.
术前mFOLFIRINOX或PAXG方案治疗I-III期胰腺导管腺癌的III期随机研究结果
讲者:Michele Reni，MD|Department of Medical Oncology，Pancreas Translational and Clinical Research Center，IRCCS San Raffaele Scientific Institute，Vita-Salute San
Raffaele University
摘要号:LBA4004
报告时间：16:12-16:24
PANOVA-3:Phase 3 study of tumor treating fields(TTFields)with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma(LA-PAC).
PANOVA-3研究：肿瘤电场治疗（TTFields）联合吉西他滨和白蛋白结合型紫杉醇治疗局部晚期胰腺导管腺癌（LA-PAC）的III期研究
讲者:Vincent J.Picozzi，MD，MMM|Virginia Mason Medical Center
摘要号:LBA4005
报告时间：16:24-16:36
Preliminary results from the randomized phase 2 study(1801 part 3B)of elraglusib in combination with gemcitabine/nab-paclitaxel(GnP)versus GnP alone in patients(pts)with previously untreated metastatic pancreatic ductal adenocarcinoma(mPDAC).
Elraglusib联合吉西他滨/白蛋白结合型紫杉醇（GnP）对比GnP单药治疗初治转移性胰腺导管腺癌（mPDAC）的随机II期研究（1801 part3B）初步结果
讲者:Devalingam Mahalingam，MD，PhD|Robert H.Lurie Comprehensive Cancer Center，Northwestern University
摘要号:4006
报告时间：16:36-16:48
肝胆肿瘤
A phase III randomized clinical trial evaluating perioperative therapy(neoadjuvant chemotherapy versus chemoradiotherapy)in locally advanced gallbladder cancers(POLCAGB).
POLCAGB研究：局部晚期胆囊癌围手术期治疗（新辅助化疗对比放化疗）的III期随机临床试验
讲者:Reena Engineer，DNB|Tata Memorial Centre(HBNI)
摘要号:4007
报告时间：17:12-17:24
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer:Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.
AIO/CALGP/ACO-GAIN III期研究：吉西他滨联合顺铂新辅助化疗后根治性肝切除对比直接根治性肝切除，再行辅助治疗胆道癌的最终结果
讲者:Thorsten Oliver Goetze|Institute of Clinical Cancer Research(IKF)，Krankenhaus Nordwest，UCT-University Cancer Center
摘要号:4008
报告时间：17:24-17:36
结直肠癌和肛门癌专场
Gastrointestinal Cancer—Colorectal and Anal
美国东部时间：5月30日14:45–17:45
北京时间：5月31日03:45–06:45
地点：Arie Crown Theater
First-line encorafenib+cetuximab+mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer(BREAKWATER):Progression-free survival and updated overall survival analyses.
BREAKWATER研究：一线康奈非尼（encorafenib）+西妥昔单抗（cetuximab）+mFOLFOX6方案治疗BRAF V600E突变转移性结直肠癌：无进展生存期及总生存期更新
讲者:Elena Elez，MD，PhD|Department of Medical Oncology，Vall d’Hebron University Hospital(HUVH)，Vall d’Hebron Institute of Oncology(VHIO)，IOB-Quiron，UVic-UCC
摘要号:LBA3500
报告时间：14:45-14:57
Nivolumab(NIVO)plus ipilimumab(IPI)vs chemotherapy(chemo)or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient(MSI-H/dMMR)metastatic colorectal cancer(mCRC):Expanded analyses from CheckMate 8HW.
CheckMate 8HW研究的扩展分析：纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）对比化疗（chemo）或NIVO单药治疗微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）转移性结直肠癌（mCRC）
讲者:Heinz-Josef Lenz，MD|University of Southern California Norris Comprehensive Cancer Center
摘要号:3501
报告时间：14:57-15:09
Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type，unresectable metastatic colorectal cancer:A multicenter，prospective，randomised，phase 3 clinical trial(ANCHOR trial).
ANCHOR研究：安罗替尼（anlotinib）对比贝伐珠单抗（bevacizumab）联合标准一线化疗治疗RAS/BRAF野生型不可切除转移性结直肠癌：多中心、前瞻性、随机III期临床试验
讲者:丁克峰教授|浙江大学医学院附属第二医院
摘要号:LBA3502
报告时间：15:09-15:21
ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer:Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial(intergroup study of AGITG and CCTG).
AGITG dynamic-III研究：ctDNA指导的III期结肠癌辅助强化治疗，随机AGITG dynamic-III研究（AGITG与CCTG合作）ctDNA阳性队列初步分析
讲者:Jeanne Tie，MD，FRACP，MBChB|Department of Medical Oncology，Peter MacCallum Cancer Centre and Personalised Oncology Division，Walter and Eliza Hall Institute of Medical Research
摘要号:3503
报告时间：15:45-15:57
Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy(Alliance N0147).
Alliance N0147研究：基于FOLFOX辅助化疗的III期试验中无组织ctDNA检测与患者结局
讲者:Frank A.Sinicrope，MD|Mayo Clinic Rochester
摘要号:3504
报告时间：15:57-16:09
Perioperative systemic therapy for resectable colorectal peritoneal metastases:A multicenter randomized phase 3 trial(CAIRO6).
CAIRO6研究：可切除结直肠腹膜转移的围手术期系统治疗，一项多中心随机III期研究
讲者:Ignace De Hingh，MD，PhD|Catharina Cancer Institute
摘要号:3505
报告时间：16:09-16:21
Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer(mCRC):CodeBreaK 101(phase 1b).
CodeBreaK 101研究（Ib期）：索托拉西布（sotorasib）联合帕尼单抗（panitumumab）和FOLFIRI治疗经治KRAS G12C突变转移性结直肠癌（mCRC）的长期安全性和疗效
讲者:John H.Strickler，MD|Duke University Medical Center
摘要号:3506
报告时间：16:45-16:57
Efficacy and safety of olomorasib，a second-generation KRAS G12C inhibitor，plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.
第二代KRAS G12C抑制剂奥洛莫拉西布（olomorasib）联合西妥昔单抗治疗KRAS G12C突变晚期结直肠癌的疗效与安全性
讲者:Antoine Hollebecque，MD|Institut Gustave Roussy
摘要号:3507
报告时间：16:57-17:09
The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer(CRC):Results from KANDLELIT-001.
KANDLELIT-001研究结果：KRAS G12C抑制剂MK-1084治疗KRAS G12C突变晚期结直肠癌（CRC）
讲者:Iwona A.Lugowska，MD，PhD|Maria Sklodowska-Curie National Research Institute and Oncology Centre
摘要号:3508
报告时间：17:09-17:21
快速口头报告
胃食管癌及肝胆胰癌专场
Gastrointestinal Cancer—Gastroesophageal，Pancreatic，and Hepatobiliary
美国东部时间：6月2日11:30–13:00
北京时间：6月3日00:30–02:00
地点：Hall D2
Disitamab vedotin(DV)plus toripalimab(Tor)and chemotherapy(C)/trastuzumab(Tra)as first-line(1L)treatment of patients(pts)with HER2-expressing locally advanced or metastatic(la/m)gastric cancer.
维迪西妥单抗（DV）联合特瑞普利单抗（Tor）及化疗（C）/曲妥珠单抗（Tra）一线（1L）治疗HER2表达局部晚期或转移性（la/m）胃癌患者（pts）
讲者:沈琳教授|北京大学肿瘤医院
摘要号:LBA4012
报告时间11:30-11:36
Long-term outcomes and overall survival(OS)for zanidatamab+chemotherapy in HER2-positive(HER2+)advanced or metastatic gastroesophageal adenocarcinoma(mGEA):4-year follow-up of a phase 2 trial.
泽尼达妥单抗联合化疗治疗HER2阳性（HER2+）晚期或转移性胃食管腺癌（mGEA）的长期结局及总生存期（OS）：II期研究4年随访结果
讲者:Elena Elimova，MD|Princess Margaret Cancer Centre
摘要号:4013
报告时间：11:36-11:42
Recurrence patterns in the prospective，randomized，controlled，multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.
ESOPEC研究：食管腺癌患者围手术期化疗对比术前放化疗的复发模式分析，一项前瞻性、随机、对照、多中心III期研究
讲者:Jens Hoeppner，MD，FAChirg，FACS|University of Bielefeld，University Medical Center OWL，Campus Hospital Lippe
摘要号:4014
报告时间：11:42-11:48
Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer:A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.
解析胃癌对Claudin18.2-CAR-T细胞CT041的反应和耐药特征：1期临床试验的多组学探索性生物标志物分析
讲者:彭昊昕教授|北京大学肿瘤医院
摘要号:4015
报告时间:12:00-12:06
Cosiporfin sodium(DVDMS)-mediated photodynamic therapy(PDT)versus treatment of physician’s choice(TPC)in patients(pts)with advanced esophageal cancer(aEC):A phase III，randomized，open-label，multicenter trial.
Cosiporfin sodium（DVDMS）介导的光动力疗法（PDT）对比医生选择的治疗（TPC）用于晚期食管癌患者：一项III期、随机、开放标签、多中心试验
讲者:周俊教授|北京大学肿瘤医院
摘要号:4016
报告时间:12:06-12:12
Claudin18.2(CLDN18.2)expression and efficacy in pancreatic ductal adenocarcinoma(PDAC):Results from a phase I dose expansion cohort evaluating IBI343.
Claudin18.2（CLDN18.2）在胰腺导管腺癌（PDAC）中的表达及疗效：IBI343的I期剂量扩展队列研究结果
讲者:虞先濬教授|复旦大学附属肿瘤医院
摘要号:4017
报告时间:12:12-12:18
Clinical activity of EBC-129，a first-in class，anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate(ADC)，in patients with pancreatic ductal adenocarcinoma(PDAC)in a phase 1 study.
首创抗N256糖基化CEACAM5/CEACAM6抗体偶联药物（ADC）EBC-129在胰腺导管腺癌（PDAC）患者中的I期临床活性
讲者:Robert William Lentz，MD|Division of Medical Oncology，Department of Medicine，University of Colorado Anschutz School of Medicine
摘要号:4018
报告时间：12:30-12:36
10-year follow up of a phase 2 clinical trial of pembrolizumab(pembro)in microsatellite instability-high(MSI-H)/mismatch repair deficient(dMMR)advanced solid tumors.
帕博利珠单抗（pembro）治疗微卫星高度不稳定（MSI-H）/错配修复缺陷（dMMR）晚期实体瘤的II期临床试验10年随访结果
讲者:Katherine M.Bever，MD|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
摘要号:4019
报告时间：12:36-12:42
Health-related quality of life(HRQOL)in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors(NET)after progression on prior therapy(CABINET，Alliance A021602).
CABINET研究：卡博替尼对比安慰剂治疗既往治疗后进展的晚期神经内分泌肿瘤（NET）的III期试验（CABINET，Alliance A021602）中健康相关生活质量（HRQOL）分析
讲者:Amylou C.Dueck，PhD|Alliance Statistics and Data Management Center，Mayo Clinic
摘要号:4020
报告时间：12:42-12:48
结直肠癌和肛门癌专场
Gastrointestinal Cancer—Colorectal and Anal
美国东部时间：6月1日11:30–13:00
北京时间：6月2日00:30–02:00
地点：Hall D1
Upfront modified FOLFOXIRI plus panitumumab(pan)versus FOLFOX/pan for unresectable RAS and BRAF wild-type(wt)metastatic colorectal cancer(mCRC)patients:Overall survival(OS)results from the phase III TRIPLETE study by GONO.
TRIPLETE研究：前期改良FOLFOXIRI联合帕尼单抗（pan）对比FOLFOX/pan治疗不可切除RAS和BRAF野生型（wt）转移性结直肠癌（mCRC），GONO III期TRIPLETE研究总生存期（OS）结果
讲者:Veronica Conca，MD|Department of Translational Research and New Technologies in Medicine and Surgery，University of Pisa&Unit of Medical Oncology 2，Azienda Ospedaliera Universitaria Pisana
摘要号:3512
报告时间：11:30-11:36
FIRE-4(AIO KRK-0114):Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.
FIRE-4（AIO KRK-0114）研究：在FOLFIRI联合西妥昔单抗一线治疗有效的转移性RAS野生型结直肠癌，评估西妥昔单抗再挑战的效果
讲者:Lena Weiss，MD|Department of Medicine III，University Hospital Munich LMU
摘要号:3513
报告时间：11:36-11:42
Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer(mCRC):The REMARRY&PURSUIT trials.
REMARRY与PURSUIT研究：RAS/BRAF野生型转移性结直肠癌（mCRC）中循环肿瘤DNA（ctDNA）纵向监测及抗EGFR再挑战结局预测
讲者:Yoshinori Kagawa，MD，PhD|Department of Gastroenterological Surgery，Osaka International Cancer Institute
摘要号:3514
报告时间：11:42-11:48
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA(ctDNA):Results of the phase II randomized PARERE trial by GONO.
PARERE研究：帕尼单抗再治疗后序贯瑞戈非尼对比反向序贯治疗RAS/BRAF野生型循环肿瘤DNA（ctDNA）化疗难治性转移性结直肠癌患者：GONO II期随机PARERE研究结果
讲者:Chiara Cremolini，MD，PhD|Unit of Medical Oncology 2，Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery，University of Pisa
摘要号:LBA3515
报告时间：12:00-12:06
JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma(mCRC):Results of a randomized，controlled，open-label，phase II study.
JMT101联合伊立替康及SG001对比瑞戈非尼治疗转移性结直肠腺癌（mCRC）：一项随机、对照、开放标签II期研究结果
讲者:许剑民教授|复旦大学附属中山医院
摘要号:LBA3516
报告时间：12:06-12:12
Phase 2 dose expansion study of DSP107，a first-in-class bi-specific 4-1BB T-cell engager，with and without atezolizumab in metastatic MSS colorectal cancer patients.
DSP107（首创双特异性4-1BB T细胞衔接器）联合或不联合阿替利珠单抗治疗转移性微卫星稳定（MSS）结直肠癌的II期剂量扩展研究
讲者:Anwaar Saeed，MD|University of Pittsburgh Medical Center(UPMC)and UPMC Hillman Cancer Center
摘要号:3517
报告时间：12:12-12:18
Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation.
循环肿瘤DNA（ctDNA）作为肛门鳞状细胞癌放化疗早期疗效指标的研究
讲者:Aron Bercz，MD|Memorial Sloan Kettering Cancer Center
摘要号:3518
报告时间：12:30-12:36
Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer:A prospective，randomized controlled trial(SPRING-01).
SPRING-01研究：短程放疗后序贯信迪利单抗和CAPOX作为局部晚期直肠癌的全程新辅助治疗：一项前瞻性、随机对照试验
讲者:靖昌庆教授|山东省立医院
摘要号:3519
报告时间：12:36-12:42
Proposed changes to the pathologic staging for colon cancer(CC):AJCC Colon Cancer Expert Panel(AJCCCCEP).
结肠癌（CC）病理分期修订建议：AJCC结肠癌专家委员会（AJCCCCEP）提案
讲者:Qian Shi，PhD|Department of Quantitative Science Research，Mayo Clinic Rochester
摘要号:3520
报告时间：12:42-12:48
临床科学研讨会（Clinical Science Symposium）
胰腺癌创新生物标志物与疫苗专场
Innovative Biomarkers and Vaccines in Pancreatic Cancer
美国东部时间：6月2日08:00–09:30
北京时间：6月2日20:00–21:30
地点：Hall D2
Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX(FFX)induction in patients(Pts)with advanced pancreatic ductal adenocarcinoma(aPDAC):Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.
FOLFIRINOX（FFX）诱导治疗后OSE2101联合FOLFIRI对比单用FOLFIRI维持治疗晚期胰腺导管腺癌（aPDAC）患者（Pts）：随机研究TEDOPAM GERCOR D17-01 PRODIGE 63的主要终点结果
讲者:Cindy Neuzillet，MD|Department of Medical Oncology，Curie Institute
摘要号:4009
报告时间：08:12-08:24
Efficacy and safety of cafelkibart(LM-108)，an anti-CCR8 monoclonal antibody，in combination with anti-PD-1 therapy in patients with pancreatic cancer:Results from phase 1/2 studies.
抗CCR8单克隆抗体caflekibart（LM-108）联合抗PD-1治疗胰腺癌患者的疗效与安全性：I/II期研究结果
讲者:龚继芳教授|北京大学肿瘤医院
摘要号:4010
报告时间：08:24-08:36
NeoPancONE:GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma(r-PDAC):A multicentre phase II study.
NeoPancONE研究：GATA6表达作为可切除胰腺癌（r-PDAC）围手术期改良FOLFIRINOX治疗获益的预测标志物，一项多中心II期研究
讲者:Ronan Andrew McLaughlin，MBBCh|Division of Medical Oncology and Hematology，Princess Margaret Cancer Centre–University Health Network，University of Toronto
摘要号:4011
报告时间：08:48-09:00
结直肠癌的支持疗法——堪比药物？
Adjunctive Therapies in Colon Cancer—As Good As a Drug?
美国东部时间：6月1日16:30–18:00
北京时间：6月2日05:30–07:00
地点：Hall B1
CALGB/SWOG 80702（Alliance）研究结果：经验性膳食炎症模式（EDIP）与III期结肠癌患者生存期的关联
Association between empirical dietary inflammatory pattern(EDIP)and survival in patients with stage III colon cancer:Findings from CALGB/SWOG 80702(Alliance).
讲者:Sara K Char，MD|Department of Medical Oncology，Dana-Farber Cancer Institute
摘要号:LBA3509
报告时间：16:42-16:54
A randomized phase III trial of the impact of a structured exercise program on disease-free survival(DFS)in stage 3 or high-risk stage 2 colon cancer:Canadian Cancer Trials Group(CCTG)CO.21(CHALLENGE).
CHALLENGE研究：结构化运动计划对III期或高风险II期结肠癌患者无病生存期（DFS）影响的III期随机试验：加拿大癌症试验组（CCTG）CO.21（CHALLENGE研究）
讲者:Christopher M.Booth，MD|Queen’s University
摘要号:LBA3510
报告时间：16:54-17:06
Aspirin as secondary prevention for colorectal cancer liver metastases(ASAC):A multicenter，randomized，double-blind，placebo-controlled，phase 3 trial.
讲者:Sheraz Yaqub，MD，PhD|Department of Hepato-Pancreato-Biliary Surgery，Oslo University Hospital and University of Oslo，Institute of Clinical Medicine
ASAC研究：阿司匹林作为结直肠癌肝转移（CRLM）二级预防的III期多中心、随机、双盲、安慰剂对照试验
摘要号:LBA3511
报告时间：17:18-17:30
京公网安备 11010502033352号